amlodipine has been researched along with Metabolic Syndrome in 40 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine whether addition of amlodipine (5 mg)/atorvastatin (10 mg) A/A to Therapeutic Lifestyle change intervention (TLC) would beneficially modulate Metabolic Syndrome (MetS) and oxidized low-density lipoprotein (Ox-LDL) levels." | 9.34 | Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin. ( Abate, N; Chandalia, M; Jialal, I; Sallam, HS; Tuvdendorj, DR, 2020) |
| " The authors aimed to analyze the effect of olmesartan 80 mg (OLM 80) vs 20 mg (OLM 20) vs amlodipine 5 mg (AML 5) on central hemodymamics and ambulatory BP in patients with metabolic syndrome (MetS)." | 9.20 | Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. ( Ott, C; Raff, U; Schmieder, RE; Schneider, MP; Walker, S, 2015) |
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 9.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| " Manidipine was associated with a slightly greater increase in insulin sensitivity than manidipine/lisinopril, but manidipine/lisinopril was significantly more effective than manidipine and telmisartan for improving a number of metabolic, inflammatory, prothrombotic and growth/adhesion markers." | 9.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "These data support the added value of manidipine in renal and metabolic protection beyond blood pressure reduction in the treatment of hypertensive patients with metabolic syndrome." | 9.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| "Double-blind, controlled trial, designed to investigate the effects of 2-months treatment with amlodipine and olmesartan on oxidized non-esterified fatty acids (ox-NEFA), and lipopolysaccharide-stimulated cytokine production in whole blood among 23 hypertensive subjects with the metabolic syndrome." | 9.14 | Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. ( Rosenson, RS, 2009) |
| "To study effects of calcium antagonist amlodipine (normodipine) on blood pressure, heart rate variability (HRV) and carbohydrate metabolism in patients with metabolic syndrome (MS)." | 9.13 | [Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 9.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "To assess efficacy of monotherapy with ACE inhibitor lisinopril (diroton) or calcium antagonist amlodipine (normodipine) and their combination in patients with metabolic syndrome (MS)." | 9.13 | [Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "To study effects of two hypotensive drugs--normodipin and spirapril--on intravascular activity of platelets in patients with metabolic syndrome (MS)." | 9.12 | [A comparative analysis of normodipin and spirapril effects on intravascular activity of platelets in patients with metabolic syndrome]. ( Medvedev, IN, 2007) |
| "In patients with the metabolic syndrome, doxazosin treatment not only decreases platelet activity, as measured by a change in MPV, but also improves metabolic abnormalities." | 9.12 | Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. ( Basar, M; Demirtunc, R; Duman, D, 2007) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 9.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| "In order to evaluate therapeutic effects of amlodipine on intravascular thrombocyte activity (ITA) in patients having arterial hypertension (AH) with metabolic syndrome (MS), 20 patients were treated with amlodipine for 1 month." | 9.11 | [Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome]. ( Gromnatskiĭ, NI; Medvedev, IN, 2005) |
| "Aim To study the psychological continuum in elderly patients with arterial hypertension associated with metabolic syndrome during the chronotherapy with a fixed combination (FC) of amlodipine, lisinopril, and rosuvastatin." | 8.02 | Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. ( Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "These data suggest that cilnidipine suppressed the development of proteinuria greater than amlodipine possibly through inhibiting N-type calcium channel-dependent podocyte injury in SHR/ND." | 7.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 7.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 7.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| "To examine whether addition of amlodipine (5 mg)/atorvastatin (10 mg) A/A to Therapeutic Lifestyle change intervention (TLC) would beneficially modulate Metabolic Syndrome (MetS) and oxidized low-density lipoprotein (Ox-LDL) levels." | 5.34 | Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin. ( Abate, N; Chandalia, M; Jialal, I; Sallam, HS; Tuvdendorj, DR, 2020) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 5.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| " The authors aimed to analyze the effect of olmesartan 80 mg (OLM 80) vs 20 mg (OLM 20) vs amlodipine 5 mg (AML 5) on central hemodymamics and ambulatory BP in patients with metabolic syndrome (MetS)." | 5.20 | Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. ( Ott, C; Raff, U; Schmieder, RE; Schneider, MP; Walker, S, 2015) |
| "A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)." | 5.19 | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014) |
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 5.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "This was a prospective trial of amlodipine 10 mg/day administered for 1 month in primary-care patients with hypertension (n = 28), 46% of whom were obese and 57% of whom displayed the metabolic syndrome." | 5.15 | Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. ( Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011) |
| " Manidipine was associated with a slightly greater increase in insulin sensitivity than manidipine/lisinopril, but manidipine/lisinopril was significantly more effective than manidipine and telmisartan for improving a number of metabolic, inflammatory, prothrombotic and growth/adhesion markers." | 5.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "Double-blind, controlled trial, designed to investigate the effects of 2-months treatment with amlodipine and olmesartan on oxidized non-esterified fatty acids (ox-NEFA), and lipopolysaccharide-stimulated cytokine production in whole blood among 23 hypertensive subjects with the metabolic syndrome." | 5.14 | Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. ( Rosenson, RS, 2009) |
| "These data support the added value of manidipine in renal and metabolic protection beyond blood pressure reduction in the treatment of hypertensive patients with metabolic syndrome." | 5.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| "To study effects of calcium antagonist amlodipine (normodipine) on blood pressure, heart rate variability (HRV) and carbohydrate metabolism in patients with metabolic syndrome (MS)." | 5.13 | [Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 5.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "To assess efficacy of monotherapy with ACE inhibitor lisinopril (diroton) or calcium antagonist amlodipine (normodipine) and their combination in patients with metabolic syndrome (MS)." | 5.13 | [Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 5.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| "In patients with the metabolic syndrome, doxazosin treatment not only decreases platelet activity, as measured by a change in MPV, but also improves metabolic abnormalities." | 5.12 | Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. ( Basar, M; Demirtunc, R; Duman, D, 2007) |
| "To study effects of two hypotensive drugs--normodipin and spirapril--on intravascular activity of platelets in patients with metabolic syndrome (MS)." | 5.12 | [A comparative analysis of normodipin and spirapril effects on intravascular activity of platelets in patients with metabolic syndrome]. ( Medvedev, IN, 2007) |
| "In order to evaluate therapeutic effects of amlodipine on intravascular thrombocyte activity (ITA) in patients having arterial hypertension (AH) with metabolic syndrome (MS), 20 patients were treated with amlodipine for 1 month." | 5.11 | [Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome]. ( Gromnatskiĭ, NI; Medvedev, IN, 2005) |
| "Aim To study the psychological continuum in elderly patients with arterial hypertension associated with metabolic syndrome during the chronotherapy with a fixed combination (FC) of amlodipine, lisinopril, and rosuvastatin." | 4.02 | Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. ( Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021) |
| "Hypertension is a highly prevalent disease and a strong risk factor for cardiovascular disease in industrialized countries in Europe and North America." | 3.83 | [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. ( Kékes, E, 2008) |
| "Telmisartan exerted anti-obesity effects and restored leptin sensitivity, given as a treatment to rats with obesity." | 3.80 | Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "These data suggest that cilnidipine suppressed the development of proteinuria greater than amlodipine possibly through inhibiting N-type calcium channel-dependent podocyte injury in SHR/ND." | 3.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 3.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 3.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| " Long-term administration of normodipin is able to stabilize the achieved effect." | 1.34 | [Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome]. ( Medvedev, IN, 2007) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 1.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (52.50) | 29.6817 |
| 2010's | 17 (42.50) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sallam, HS | 1 |
| Tuvdendorj, DR | 1 |
| Jialal, I | 1 |
| Chandalia, M | 1 |
| Abate, N | 1 |
| Agarkov, NM | 1 |
| Okhotnikov, OI | 1 |
| Korneeva, SI | 1 |
| Moskaleva, EO | 1 |
| Moskalev, AA | 1 |
| Kolomiets, VI | 1 |
| Markelova, AM | 1 |
| Markelova, EA | 1 |
| Ackerman, Z | 2 |
| Grozovski, M | 2 |
| Oron-Herman, M | 3 |
| Rosenthal, T | 3 |
| Sela, BA | 3 |
| Amir, G | 1 |
| Kalyuzhin, VV | 1 |
| Teplyakov, AT | 1 |
| Pushnikova, EY | 1 |
| Bespalova, LD | 1 |
| Kalyuzhina, EV | 1 |
| Kolesnikov, RN | 1 |
| Spinar, J | 1 |
| Vitovec, J | 1 |
| Soucek, M | 1 |
| Müller-Fielitz, H | 1 |
| Hübel, N | 1 |
| Mildner, M | 1 |
| Vogt, FM | 1 |
| Barkhausen, J | 1 |
| Raasch, W | 1 |
| Raff, U | 1 |
| Walker, S | 1 |
| Ott, C | 1 |
| Schneider, MP | 1 |
| Schmieder, RE | 1 |
| Schlimpert, V | 1 |
| Toyoda, S | 1 |
| Inami, S | 1 |
| Kato, T | 1 |
| Tsukada, K | 1 |
| Nakamoto, A | 1 |
| Kikegawa, Y | 1 |
| Suzuki, A | 1 |
| Anraku, Y | 1 |
| Node, K | 1 |
| Inoue, T | 1 |
| Skibitsky, VV | 1 |
| Fendrikova, AV | 1 |
| Pyhalova, NE | 1 |
| Sirotenko, DV | 1 |
| Kékes, E | 1 |
| Praskurnichiĭ, EA | 2 |
| Shevchenko, OP | 2 |
| Savel'eva, SA | 2 |
| Martínez Martín, FJ | 1 |
| Rosenson, RS | 1 |
| Ferdinand, KC | 1 |
| Flack, JM | 1 |
| Saunders, E | 1 |
| Victor, R | 1 |
| Watson, K | 1 |
| Kursun, A | 1 |
| Jamieson, MJ | 1 |
| Shi, H | 1 |
| Fan, YY | 1 |
| Kohno, M | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kobori, H | 1 |
| Suwarni, D | 1 |
| Ohashi, N | 1 |
| Hitomi, H | 1 |
| Asanuma, K | 1 |
| Noma, T | 1 |
| Tomino, Y | 1 |
| Fujita, T | 1 |
| Nishiyama, A | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Ferrari, I | 1 |
| Mugellini, A | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Martinez-Martin, FJ | 2 |
| Rodriguez-Rosas, H | 2 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 2 |
| Pedrianes-Martin, P | 2 |
| Comi-Diaz, C | 2 |
| Macias-Batista, A | 1 |
| Thomopoulos, C | 1 |
| Tsioufis, C | 1 |
| Makris, T | 1 |
| Stefanadis, C | 1 |
| McInnes, GT | 1 |
| Hansel, B | 1 |
| Girerd, X | 1 |
| Bonnefont-Rousselot, D | 1 |
| Bittar, R | 1 |
| Chantepie, S | 1 |
| Orsoni, A | 1 |
| Bruckert, E | 1 |
| Chapman, MJ | 1 |
| Kontush, A | 1 |
| Caillier, B | 1 |
| Pilote, S | 1 |
| Patoine, D | 1 |
| Levac, X | 1 |
| Couture, C | 1 |
| Daleau, P | 1 |
| Simard, C | 1 |
| Drolet, B | 1 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Cybulski, J | 1 |
| Ceremuzyński, L | 1 |
| Medvedev, IN | 4 |
| Gromnatskiĭ, NI | 2 |
| Konda, T | 1 |
| Enomoto, A | 1 |
| Matsushita, J | 1 |
| Takahara, A | 1 |
| Moriyama, T | 1 |
| Shimabukuro, M | 1 |
| Tanaka, H | 1 |
| Shimabukuro, T | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Celik, T | 1 |
| Yenicesu, M | 1 |
| Eyileten, T | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Demirtunc, R | 1 |
| Duman, D | 1 |
| Basar, M | 1 |
| Pappo, O | 1 |
| Link, G | 1 |
| Black, HR | 2 |
| Davis, B | 1 |
| Barzilay, J | 2 |
| Nwachuku, C | 1 |
| Baimbridge, C | 2 |
| Marginean, H | 1 |
| Wright, JT | 2 |
| Basile, J | 1 |
| Wong, ND | 1 |
| Whelton, P | 1 |
| Dart, RA | 1 |
| Thadani, U | 1 |
| Harris-Haywood, S | 1 |
| Pressel, S | 1 |
| Bareis, CJ | 1 |
| Basile, JN | 1 |
| Dart, R | 1 |
| Gupta, AK | 1 |
| Hamilton, BP | 1 |
| Einhorn, PT | 1 |
| Haywood, LJ | 1 |
| Jafri, SZ | 1 |
| Louis, GT | 1 |
| Whelton, PK | 1 |
| Scott, CL | 1 |
| Simmons, DL | 1 |
| Stanford, C | 1 |
| Davis, BR | 1 |
| Toblli, JE | 1 |
| Muñoz, MC | 1 |
| Cao, G | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| de la Figuera, M | 1 |
| Honorato, J | 1 |
| Llisterri, JL | 1 |
| Segura, J | 1 |
| Calderón, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amlodipine and Metabolic Syndrome
| Article | Year |
|---|---|
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
22 trials available for amlodipine and Metabolic Syndrome
| Article | Year |
|---|---|
Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Behavior Therapy; Biomarkers; Blood Pressure; Cardiometabolic | 2020 |
[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angina, Stable; Atenolol; Calcium Channel | 2013 |
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2014 |
Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2015 |
Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2015 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
[Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Female; He | 2008 |
Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood | 2009 |
Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cell Adhe | 2009 |
Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, | 2010 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2011 |
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.
Topics: Aged; Amlodipine; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Mass Index; Calcium Ch | 2011 |
[Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Platelets; Humans; Hypertension; | 2005 |
[Normodipin in correction of platelet rheology in hypertensive patients with metabolic syndrome].
Topics: Amlodipine; Blood Platelets; Female; Humans; Hypertension; Lipid Peroxidation; Lipids; Male; Metabol | 2005 |
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Topics: Adipose Tissue, White; Adult; Aged; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor | 2007 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study.
Topics: Amlodipine; Antihypertensive Agents; Blood Platelets; Doxazosin; Female; Humans; Male; Metabolic Syn | 2007 |
[A comparative analysis of normodipin and spirapril effects on intravascular activity of platelets in patients with metabolic syndrome].
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Platelets; Blood Pressure; Enalapril; Female; Huma | 2007 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cross-Sectio | 2008 |
[Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Bl | 2008 |
18 other studies available for amlodipine and Metabolic Syndrome
| Article | Year |
|---|---|
Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin.
Topics: Aged; Amlodipine; Antihypertensive Agents; Anxiety; Blood Pressure; Chronotherapy; Humans; Hypertens | 2021 |
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Cas | 2013 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive | 2014 |
[Optimizing antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2015 |
[The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydrop | 2016 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pr | 2009 |
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Topics: Amlodipine; Animals; Base Sequence; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Bloc | 2010 |
The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Comorbidity; Drug Therapy, Com | 2011 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes | 2011 |
Metabolic syndrome potentiates the cardiac action potential-prolonging action of drugs: a possible 'anti-proarrhythmic' role for amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Diet, High-Fat; Electrocardiography; Guinea Pigs; Hear | 2012 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
[Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Doxazosin; Fem | 2002 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; F | 2005 |
The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Ca | 2005 |
[Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Adult; Amlodipine; Antihypertensive Agents; Antioxidants; Benzopyrans; Ethanolamines; Female; Hemost | 2007 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolip | 2008 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |